Healthcare Professionals

Welcome To BRUKINSA.CA

I am a healthcare professional

I am a patient

This website is intended for Canadian Healthcare Professionals only. Please select your indication of primary interest. You can easily switch between
the cancer type you’d like to learn more about once you have entered the site.

To access the site, please enter your license number.

Waldenström's Macroglobulinemia

Mantle Cell Lymphoma

MCL

Marginal Zone Lymphoma

MZL

Chronic Lymphocytic Leukemia

CLL

This website is intended for Canadian patients
who have been prescribed BRUKINSA^® (zanubrutinib).

To access the site, please enter the 8-digit DIN found on your BRUKINSA package.

What is a DIN?DIN stands for Drug Identification Number, which is the 8-digit number assigned to each drug.

Where can I find the DIN?The DIN for BRUKINSA can be found on your BRUKINSA package. Image of location of DIN on package.

Please select the type of cancer for which you've been prescribed BRUKINSA.

Waldenström's Macroglobulinemia

Mantle Cell Lymphoma

MCL

NOW INDICATED IN

Chronic Lymphocytic Leukemia (CLL)

For treatment-naïve and relapsed or refractory patients

Access:
SEQUOIA Study

BRUKINSA vs. BR
in TN CLL

Access:
ALPINE Study

BRUKINSA vs. ibrutinib
in R/R CLL

Download Product
Monograph
(PDF, 525 KB) Contact Your
Regional Manager

BR=bendamustine+rituximab; R/R=relapsed/refractory; TN=treatment-naïve.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND CLINICAL USE:

BRUKINSA (zanubrutinib) is indicated:

for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).
for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
for the treatment of adult patients with chronic lymphocytic leukemia (CLL).

Pediatrics (<18 years of age):
No safety and efficacy data are available; therefore, Health Canada has not authorized an indication for pediatric use.
Geriatrics (>65 years of age):
No clinically relevant differences in safety or efficacy were observed between patients ≥65 years and those younger than 65 years.

CONTRAINDICATIONS:

BRUKINSA is contraindicated in patients who are hypersensitive to zanubrutinib or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.

Most Serious Warnings and Precautions:

Healthcare professional supervision required:
Treatment with BRUKINSA should be initiated and supervised by a Qualified Healthcare Practitioner experienced in the use of anticancer therapies.
Serious hemorrhage:
(see the BRUKINSA Product Monograph, WARNINGS AND PRECAUTIONS, Hemorrhage).

OTHER RELEVANT WARNINGS AND PRECAUTIONS:

Second primary malignancies:
Monitor patients for skin cancer and advise patients to use sun protection.
Atrial fibrillation and flutter:
Monitor for signs and symptoms of atrial fibrillation and atrial flutter and manage as appropriate.
Driving and operating machinery:
Fatigue, dizziness, and asthenia have been reported in some patients taking BRUKINSA and should be considered when assessing a patient’s ability to drive or operate machines.
Cytopenias:
Monitor complete blood counts regularly during treatment.
Infections:
Monitor patients for signs and symptoms of infection and treat appropriately. Consider prophylaxis according to standard of care in patients who are at increased risk for infections.
Tumour lysis syndrome:
Monitor patients closely and treat as appropriate.
Peri-operative considerations:
Consider the benefit-risk of withholding BRUKINSA for 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.
Fertility:
No data on the effects of BRUKINSA on fertility in humans are available.
Teratogenic risk:
Advise women of the potential hazard to a fetus and to avoid becoming pregnant during treatment and for at least 1 week after the last dose of BRUKINSA. Advise men to avoid fathering a child while receiving BRUKINSA and for at least 3 months following the last dose of BRUKINSA.
Breastfeeding:
Advise lactating women not to breastfeed during treatment with BRUKINSA and for at least two weeks following the last dose.
Interstitial lung disease (ILD):
Monitor patients for signs and symptoms of ILD.
Hemorrhage:
Patients should be monitored for signs of bleeding.

For more information:

Please consult the BRUKINSA Product Monograph for important information relating to adverse reactions, drug interactions, and dosing information, which has not been discussed in this piece. The Product Monograph is also available by calling 1-877-828-5598.